Targeted Therapies in Cancer: An Update


Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Besides surgery, radiation therapy, endocrine therapy or chemotherapy, which were widely used in cancer patients for decades, the 21st century has seen the emergence of “targeted” therapy, resulting from the identification of molecular pathways in cells and their alterations in tumors. An increasing number of compounds targeting specific molecules or cancer cells have been developed and, for some of them, approved by the United States Food and Drug Administration (FDA) as well as other regulators in EU and Japan Additional new and more efficient types of compounds, are still in clinical trials, but are expected to gain future approval.

More than eighty FDA-approved targeted therapies are described here, along with about eighty other promising compounds. These drugs are members of various therapy classes, including tyrosine kinase inhibitors; serine/threonine kinase inhibitors; dual specificity kinase inhibitors; lipid kinase inhibitors; poly ADP ribose polymerase inhibitors; monoclonal antibodies; microtubule targeting agents; histone deacetylase inhibitors; proteasome inhibitors; antimetabolites; immunomodulatory agents; DNA methyltransferase inhibitors; hedgehog pathway inhibitors; enzymes; protein translation inhibitors; vaccines, oncolytic viruses; chimeric antigen receptor T-cells (CAR-T); and so on.

A series of “companion” diagnostics intended to be used as an indication for specific therapies, and approved to this aim are also mentioned.

The book aims to present the broad landscape of compounds and companion diagnostics that are expected to pave the way towards a future of hope for cancer patients. (Imprint: Nova Biomedical)

Table of Contents

Table of Contents



Chapter 1. Innovation in the Biopharmaceutical Pipeline

Chapter 2. The Diversity of Targeted Cancer Drugs Recently Approved by the FDA

Chapter 3. Chronological List of Targeted Cancer Drugs Approved by the FDA

Chapter 4. Targeted Therapies: Detailed Description

Chapter 5. Targeted Therapies in the Pipe-Line

Chapter 6. Companion Diagnostics for Targeted Therapies

About the Author


Audience: Academic level: the book is intended for MSc, MD, PhD’s and, more generally, to researchers in oncology. However, it may be of interest for people in pharmaceutical industry, since there is a continuous search for new gene-based targeted therapies.

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!